Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2 − advanced breast cancer (PALOMA-1, TRIO-18)

ConclusionsPalbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS.Pfizer Inc (NCT00721409)

Source: Breast Cancer Research and Treatment - July 26, 2020 Category: Cancer & Oncology Source Type: research